Compare PRPO & ICMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRPO | ICMB |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Finance: Consumer Services |
| Sector | Industrials | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 42.2M |
| IPO Year | 2000 | 2013 |
| Metric | PRPO | ICMB |
|---|---|---|
| Price | $24.85 | $2.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.9K | ★ 36.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 17.63% |
| EPS Growth | ★ 35.03 | N/A |
| EPS | N/A | ★ 0.04 |
| Revenue | ★ $18,532,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.75 |
| P/E Ratio | ★ N/A | $73.25 |
| Revenue Growth | ★ 21.95 | N/A |
| 52 Week Low | $4.90 | $2.46 |
| 52 Week High | $28.50 | $3.38 |
| Indicator | PRPO | ICMB |
|---|---|---|
| Relative Strength Index (RSI) | 59.14 | 52.24 |
| Support Level | $22.58 | $2.75 |
| Resistance Level | $26.16 | $3.05 |
| Average True Range (ATR) | 1.42 | 0.09 |
| MACD | 0.27 | -0.01 |
| Stochastic Oscillator | 99.52 | 28.57 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
Investcorp Credit Management BDC Inc is an externally managed, non-diversified closed-end management investment firm that has elected to be regulated as a business development company (BDC). Its investment objective is to maximize total return to stockholders in the form of current income and capital appreciation by investing in debt and related equity of privately held lower middle-market companies. The company principally invests in the debt of middle-market companies, which it defines as those companies that have an enterprise value.